Literature DB >> 11082461

Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself.

D S Reddy1, M A Rogawski.   

Abstract

Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnane-20-one), an orally active synthetic analog of the neuroactive steroid allopregnanolone, is a positive allosteric modulator of gamma-aminobutyric acid(A) receptors with anticonvulsant properties. We sought to determine whether tolerance occurs to the anticonvulsant activity of ganaxolone in the pentylenetetrazol seizure test and whether there is cross-tolerance with diazepam. Rats were treated with two daily injections of a 2 x ED(50) dose of ganaxolone (7 mg/kg s.c.), diazepam (4 mg/kg i.p.), or vehicle for 3 or 7 days. On the day after the chronic treatment periods, the anticonvulsant potencies of ganaxolone and diazepam were determined. The ED(50) values for ganaxolone after 3- and 7-day treatment with ganaxolone were not significantly different from that in naive rats (ED(50) = 3.5 mg/kg). In contrast, in animals that were treated chronically with ganaxolone for 7 days, there was a significant reduction in the anticonvulsant potency of diazepam (ED(50) = 4.0 versus 1.9 mg/kg for naive controls). Chronic treatment with diazepam was not associated with a reduction in the potency of ganaxolone, but there was a reduction in the potency of diazepam (ED(50) = 3.7 mg/kg). Plasma ganaxolone determinations indicated that the pharmacokinetic properties of ganaxolone were unchanged after 7-day chronic ganaxolone treatment. The estimated equilibrium plasma concentrations of ganaxolone associated with threshold (750-950 ng/ml) and 50% seizure protection (1215-1295 ng/ml) were similar in naive and chronically treated rats. We conclude that there is no tolerance to the anticonvulsant activity of ganaxolone nor is there cross-tolerance to ganaxolone when tolerance develops to diazepam. However, there is cross-tolerance to diazepam with chronic ganaxolone treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082461

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

1.  Genotype Differences in Sensitivity to the Anticonvulsant Effect of the Synthetic Neurosteroid Ganaxolone during Chronic Ethanol Withdrawal.

Authors:  Michelle A Nipper; Jeremiah P Jensen; Melinda L Helms; Matthew M Ford; John C Crabbe; David J Rossi; Deborah A Finn
Journal:  Neuroscience       Date:  2018-12-02       Impact factor: 3.590

2.  Chronic benzodiazepine treatment does not alter interactions between positive GABA(A) modulators and flumazenil or pentylenetetrazole in monkeys.

Authors:  Lisa R Gerak; Charles P France
Journal:  Behav Pharmacol       Date:  2011-02       Impact factor: 2.293

3.  Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model.

Authors:  Doodipala S Reddy; Michael A Rogawski
Journal:  Epilepsy Res       Date:  2010-02-20       Impact factor: 3.045

Review 4.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

5.  Comparing the discriminative stimuli produced by either the neuroactive steroid pregnanolone or the benzodiazepine midazolam in rats.

Authors:  Xiang Bai; Lisa R Gerak
Journal:  Psychopharmacology (Berl)       Date:  2010-10-23       Impact factor: 4.530

Review 6.  Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake.

Authors:  Graziano Pinna; Erminio Costa; Alessandro Guidotti
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

Review 7.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

8.  Dancing the delta shuffle: neurosteroids regulate GABAA receptor expression.

Authors:  Andre Lagrange
Journal:  Epilepsy Curr       Date:  2006 Jan-Feb       Impact factor: 7.500

9.  Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol.

Authors:  M J Ramaker; M M Ford; T J Phillips; D A Finn
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

Review 10.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.